Being started on a smaller dose of the approved early Alzheimer’s therapy Kisunla was found to reduce the risk of ARIA-E on imaging scans.
Eli Lilly met the same fate with its Leqembi rival Kisunla (donanemab), which was also rejected for NHS use last month. In ...
Even a juggernaut like Eli Lilly ( LLY 2.71%) can miss the mark sometimes. When it reported its third-quarter earnings on Oct. 30, its share price plunged to the tune of 11% before recovering somewhat ...
After dosing with Cognition’s CT1812, study reports declines of 95% and higher in subgroup with below-median p-tau217.
Roughly 82 percent of Americans support requiring Medicare and insurance companies to cover the Alzheimer's treatments.
This year has seen several biopharma companies drop Alzheimer’s and Parkinson’s disease programs, but experts say plenty are ...
The Alzheimer's disease drug Kisunla will face major reimbursement challenges in the U.K. after the cost-effectiveness watchdog, NICE, said the drug isn't cost-effective.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback